Takeda Pharmaceutical: Topline results of the phase 3 clinical trial of Soticlestat (TAK-935) targeting patients with Dravet syndrome and Lennox-Gastaut syndrome.

JPX · Jun 17 18:45

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.